Analysis of whole blood tacrolimus concentrations in liver transplant patients exhibiting impaired liver function.

In transplant patients with impaired liver function, HPLC methodologies have been suggested for monitoring whole blood tacrolimus concentrations because of the reported inaccuracy of immunoassay for whole blood tacrolimus concentrations. One hundred fifty whole blood samples from 50 subjects enrolled in a multicenter liver transplant trial were chosen for HPLC/MS/MS analysis without consideration of the clinical status of the patient at the time of sampling. These samples were chosen to represent the sampling intervals during the 12-week posttransplantation period. Retrospectively, the authors identified a subset of 39 samples from 27 subjects exhibiting impaired liver function as demonstrated by bilirubin concentrations > 3.0 mg/dL (mean +/-SD = 7.5 +/- 5.6 mg/dL). The authors compared the agreement of concentrations obtained from the PRO-Trac II ELISA and HPLC/MS/MS by least squares linear regression analysis and Bland/Altman analysis, in this subset against the agreement of concentrations for 76 samples with normal bilirubin. In the samples obtained from patients with impaired liver function the resulting regression equation was: ELISA = 1.19(HPLC) + 0.7; r = 0.9. The mean difference (HPLC/MS/MS - ELISA) was -2.5 ng/mL +/- 2.9 ng/mL (mean +/- SD). While 71% of samples agreed within 3 ng/mL, 3% (n = 1) exhibited a difference >10 ng/ml. The corresponding evaluation of the samples with normal bilirubin concentrations resulted in the regression equation ELISA = 0.96(HPLC) + 0.9; r = 0.9, and a mean difference of -0.6 ng/mL +/- 2.3 ng/mL. The authors conclude that while a small subset of patients with cholestasis may require closer evaluation with a more specific methodology, the majority of the patients may be satisfactorily monitored with the PRO-Trac II ELISA.

[1]  L. Shaw,et al.  Analytical validation of the PRO-Trac II ELISA for the determination of tacrolimus (FK506) in whole blood. , 1999, Clinical chemistry.

[2]  K. Linnet,et al.  Necessary sample size for method comparison studies based on regression analysis. , 1999, Clinical chemistry.

[3]  U. Garg,et al.  Comparison of the Abbott IMx Tacrolimus I and Tacrolimus II assays. , 1998, Clinical Chemistry.

[4]  U. Christians,et al.  Pitfalls in monitoring tacrolimus (FK 506). , 1997, Therapeutic drug monitoring.

[5]  A. Grygotis,et al.  High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with liver and renal transplants. , 1997, Therapeutic drug monitoring.

[6]  A. Alak,et al.  An HPLC/MS/MS assay for tacrolimus in patient blood samples. Correlation with results of an ELISA assay. , 1997, Journal of pharmaceutical and biomedical analysis.

[7]  A. Alak Measurement of tacrolimus (FK506) and its metabolites: a review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies. , 1997, Therapeutic drug monitoring.

[8]  P. Wong,et al.  A simplified whole blood enzyme-linked immunosorbent assay (ProTrac II) for tacrolimus (FK506) using proteolytic extraction in place of organic solvents. , 1996, Therapeutic drug monitoring.

[9]  U. Christians,et al.  Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. , 1996, Clinical chemistry.

[10]  S. Pond,et al.  Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. , 1996, Clinical chemistry.

[11]  T. Starzl,et al.  Clinical Pharmacokinetics of Tacrolimus , 1995, Clinical pharmacokinetics.

[12]  U. Christians,et al.  Consensus Document: Therapeutic Monitoring of Tacrolimus (FK‐506) , 1995 .

[13]  K. Iwasaki,et al.  Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[14]  P. Wallemacq,et al.  FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. , 1993, Clinical chemistry.

[15]  H. Schiebel,et al.  Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. , 1992, Clinical chemistry.

[16]  S. Vincent,et al.  In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. , 1992, Archives of biochemistry and biophysics.

[17]  G. Kootstra,et al.  FK 506: monitoring in plasma or in whole blood? , 1991, Transplantation proceedings.

[18]  M. Okuhara,et al.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. , 1987, The Journal of antibiotics.